Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model.
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Sanofi MS drug nears green light after pass-the-parcel marathon
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
Decreased microglial activation in MS patients treated with glatiramer acetate.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
Does interferon Beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis?
Idebenone for primary progressive multiple sclerosis
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Natalizumab Use During the Third Trimester of Pregnancy.
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.

Pages